AstraZeneca's Imfinzi gets FDA approval for lung cancer treatment
AstraZeneca
12,140.00p
14:20 17/05/24
-0.21%
-26.00p
AstraZeneca on Friday said its Imfinzi drug in combination with the Imjudo antibody and platinum-based chemotherapy has been approved in the US for the treatment of adult patients with stage IV non-small cell lung cancer.
FTSE 100
8,420.69
14:20 17/05/24
n/a
n/a
FTSE 350
4,631.56
14:20 17/05/24
n/a
n/a
FTSE All-Share
4,584.13
14:20 17/05/24
n/a
n/a
Pharmaceuticals & Biotechnology
23,342.38
14:19 17/05/24
-0.39%
-91.61
The approval by the Food and Drug Administration (FDA) was based on the results from the Poseidon Phase 3 trial.
Patients treated with a limited course of five cycles of Imjudo added to Imfinzi plus four cycles of platinum-based chemotherapy experienced a 23% reduction in the risk of death versus a range of chemotherapy options.
Reporting by Frank Prenesti for Sharecast.com